4D Molecular Therapeutics Inc (FDMT)
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company listed on the NASDAQ under the ticker FDMT. The company develops adeno-associated virus vectors using its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution, with operations in the Netherlands and the United States. Its lead candidate is 4D-150, an intravitreal gene therapy being developed for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, with the aim of enabling sustained anti-VEGF production from the retina over multiple years. The pipeline also includes 4D-710 for cystic fibrosis, 4D-175 for geographic atrophy, and 4D-725 for alpha-1 anti-trypsin deficiency lung disease, each at different development stages. The company also has collaboration and licensing arrangements with Otsuka Pharmaceutical Co., Ltd. Founded in 2013, 4D Molecular Therapeutics is headquartered in Emeryville, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FDMT
|
$13.11
|
12.1% Upside
|
Fair
|
$28.22
|
141.4% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-3.8x
|
1.4x
|
7.0x
|
579.7 M
|
178.7 M
|
3.4%
|
74.6%
|
3.4
|
—
|
80.4%
|
